Evaluation of Baricitinib Administration for Atopic Dermatitis Patients in Spain: Insights from the DAMA-S Retrospective Chart Analysis - Top-Institutions - MDSpire

Evaluation of Baricitinib Administration for Atopic Dermatitis Patients in Spain: Insights from the DAMA-S Retrospective Chart Analysis

  • By

  • Enrique Gómez de la Fuente

  • Enrique Herrera

  • Iñigo Martinez-Espronceda Esquerdo

  • David Vidal Sarró

  • Ignasi Figueras-Nart

  • Juan F. Silvestre Salvador

  • Yolanda Gilaberte

  • Sergio Santos Alarcón

  • Esther Serra-Baldrich

  • Monica Munera Campos

  • Rosa M. Moro

  • Silvia Díaz-Cerezo

  • Sebastian Moyano

  • Irene Talavera-Rodríguez

  • Mercedes Núñez

  • April 21, 2026

  • 0 min

Share

Top Institutions in Dermatology

Brief introduction explaining scope and methodology.

  • #1

    National Institute of Allergy and Infectious Diseases (NIAID), NIH
    National Institute of Allergy and Infectious Diseases (NIAID), NIH

    Bethesda, MD

    Key Differentiators

    • Dermatology
    • Immunology
    • Clinical Trials

  • #2

    Massachusetts General Hospital, Dermatology Department
    Massachusetts General Hospital, Dermatology Department

    Boston, MA

    Key Differentiators

    • Dermatology
    • Clinical Research

  • #3

    University of Pennsylvania, Perelman School of Medicine
    University of Pennsylvania, Perelman School of Medicine

    Philadelphia, PA

    Key Differentiators

    • Dermatology
    • Immunology

  • #4

    Hospital Clínic de Barcelona, Dermatology Department
    Hospital Clínic de Barcelona, Dermatology Department

    Barcelona, Catalonia

    Key Differentiators

    • Dermatology
    • Clinical Research

  • #5

    Charité – Universitätsmedizin Berlin, Department of Dermatology
    Charité – Universitätsmedizin Berlin, Department of Dermatology

    Berlin, Berlin

    Key Differentiators

    • Dermatology
    • Immunology

Original Source(s)

Evaluation of Baricitinib Administration for Atopic Dermatitis Patients in Spain: Insights from the DAMA-S Retrospective Chart Analysis

  • by Enrique Gómez de la Fuente, Enrique Herrera, Iñigo Martinez-Espronceda Esquerdo, David Vidal Sarró, Ignasi Figueras-Nart, Juan F. Silvestre Salvador, Yolanda Gilaberte, Sergio Santos Alarcón, Esther Serra-Baldrich, Monica Munera Campos, Rosa M. Moro, Silvia Díaz-Cerezo, Sebastian Moyano, Irene Talavera-Rodríguez, Mercedes Núñez

  • April 21, 2026

Related Content

FDA Drops Age Limit for Neffy

Needle-free epinephrine expands access for younger children meeting weight criteria

Topical Postbiotics Show Promise for Acne, Eczema

Postbiotics linked to improvements in acne and eczema, with limited data in rosacea

IL-17, IL-23 Therapies Lead Psoriasis Care

Network meta-analysis suggests higher PASI 90 response rates with biologics vs oral systemic therapies